Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium.
Colonoscopy
Colorectal cancer
Epidemiology
Incidence
Lynch Syndrome
Over-diagnosis
Penetrance
Prevention
Prospective
Segregation analysis
Journal
Hereditary cancer in clinical practice
ISSN: 1731-2302
Titre abrégé: Hered Cancer Clin Pract
Pays: Poland
ID NLM: 101231179
Informations de publication
Date de publication:
01 Oct 2022
01 Oct 2022
Historique:
received:
03
12
2021
accepted:
31
08
2022
entrez:
1
10
2022
pubmed:
2
10
2022
medline:
2
10
2022
Statut:
epublish
Résumé
To compare colorectal cancer (CRC) incidences in carriers of pathogenic variants of the MMR genes in the PLSD and IMRC cohorts, of which only the former included mandatory colonoscopy surveillance for all participants. CRC incidences were calculated in an intervention group comprising a cohort of confirmed carriers of pathogenic or likely pathogenic variants in mismatch repair genes (path_MMR) followed prospectively by the Prospective Lynch Syndrome Database (PLSD). All had colonoscopy surveillance, with polypectomy when polyps were identified. Comparison was made with a retrospective cohort reported by the International Mismatch Repair Consortium (IMRC). This comprised confirmed and inferred path_MMR carriers who were first- or second-degree relatives of Lynch syndrome probands. In the PLSD, 8,153 subjects had follow-up colonoscopy surveillance for a total of 67,604 years and 578 carriers had CRC diagnosed. Average cumulative incidences of CRC in path_MLH1 carriers at 70 years of age were 52% in males and 41% in females; for path_MSH2 50% and 39%; for path_MSH6 13% and 17% and for path_PMS2 11% and 8%. In contrast, in the IMRC cohort, corresponding cumulative incidences were 40% and 27%; 34% and 23%; 16% and 8% and 7% and 6%. Comparing just the European carriers in the two series gave similar findings. Numbers in the PLSD series did not allow comparisons of carriers from other continents separately. Cumulative incidences at 25 years were < 1% in all retrospective groups. Prospectively observed CRC incidences (PLSD) in path_MLH1 and path_MSH2 carriers undergoing colonoscopy surveillance and polypectomy were higher than in the retrospective (IMRC) series, and were not reduced in path_MSH6 carriers. These findings were the opposite to those expected. CRC point incidence before 50 years of age was reduced in path_PMS2 carriers subjected to colonoscopy, but not significantly so.
Identifiants
pubmed: 36182917
doi: 10.1186/s13053-022-00241-1
pii: 10.1186/s13053-022-00241-1
pmc: PMC9526951
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36Subventions
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Hered Cancer Clin Pract. 2019 Feb 28;17:8
pubmed: 30858900
Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1010-1014
pubmed: 30824524
JAMA. 2005 Nov 2;294(17):2195-202
pubmed: 16264161
Gastroenterology. 2008 Apr;134(4):988-97
pubmed: 18395080
Fam Cancer. 2020 Apr;19(2):169-175
pubmed: 31997046
Gastroenterology. 1995 May;108(5):1405-11
pubmed: 7729632
Gut. 2017 Sep;66(9):1657-1664
pubmed: 27261338
Br J Cancer. 2011 Jun 28;105(1):162-9
pubmed: 21559014
Br J Surg. 2021 May 27;108(5):484-498
pubmed: 34043773
Genet Med. 2021 Oct;23(10):1807-1817
pubmed: 34140662
Gastroenterology. 2018 Nov;155(5):1400-1409.e2
pubmed: 30063918
Hered Cancer Clin Pract. 2020 Mar 14;18:6
pubmed: 32190163
J Med Genet. 2007 Jun;44(6):353-62
pubmed: 17327285
J Clin Oncol. 2018 Oct 10;36(29):2961-2968
pubmed: 30161022
PLoS One. 2015 Mar 27;10(3):e0121980
pubmed: 25816162
Int J Cancer. 2018 Nov 1;143(9):2250-2260
pubmed: 29904935
Int J Cancer. 2021 Feb 15;148(4):800-811
pubmed: 32683684
Mod Pathol. 2018 Oct;31(10):1608-1618
pubmed: 29884888
Hered Cancer Clin Pract. 2019 Oct 14;17:28
pubmed: 31636762
Nat Med. 2020 Apr;26(4):566-576
pubmed: 32251400
Exp Mol Pathol. 2021 Oct;122:104668
pubmed: 34302852
Gut. 2013 Jun;62(6):812-23
pubmed: 23408351
Lancet Oncol. 2012 Jun;13(6):598-606
pubmed: 22552011
Lancet. 1995 May 6;345(8958):1183-4
pubmed: 7723574
Clin Cancer Res. 2020 Sep 1;26(17):4503-4510
pubmed: 32540851
Nat Med. 2020 Apr;26(4):475-484
pubmed: 32273608
Hered Cancer Clin Pract. 2017 Oct 10;15:18
pubmed: 29046738
Lancet Oncol. 2021 Jul;22(7):1014-1022
pubmed: 34111421
JAMA. 2011 Jun 8;305(22):2304-10
pubmed: 21642682
Gastroenterology. 2018 Sep;155(3):844-851
pubmed: 29758216